Lorus Therapeutics Incorporated operates in the Biological products exc. diagnostic sector. Lorus Therapeutics Inc. is a biopharmaceutical company focused on the discovery, research and development of effective anticancer therapies. The Company is building a portfolio of anticancer drugs ranging from discovery and preclinical to preparation for initiation of a Phase III clinical trial. Lorus has product candidates in three classes of anticancer therapies: ribonucleic acid (RNA)-targeted (antisense and siRNA) therapies, based on synthetic segments of DNA or RNA designed to bind to the messenger RNA that is responsible for the production of proteins over-expressed in cancer cells; small molecule therapies based on anti-angiogenic, antiproliferative and anti-metastatic agents, and immunotherapy, based on protein-based therapeutic that elicits antitumor immunity. Its lead antisense drug candidate is LOR-2040, which targets the R2 component of ribonucleotide reductase (RNR). LOR-253 is a small molecule compound discovered at Lorus and optimized for its anticancer properties. In our complete report available for purchase the company is compared to: Aastrom Biosciences, Inc., CEL-SCI Corporation and Mymetics Corporation.